title: The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.
abstract: The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML). For patient with chronic phase CML, frontline treatment with imatinib leads to an estimated event-free survival and overall survival at 8 years of 81 and 85%, respectively. Second-generation TKIs (dasatinib and nilotinib) have shown improved early cytogenetic and molecular end points compared with imatinib in frontline randomized studies. Imatinib, dasatinib and nilotinib are all now approved for the frontline therapy. Overall treatment success is dependent in large part on treatment compliance, effective management of side effects of the therapy and close monitoring and achievement of cytogenetic and molecular milestones.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA.
authors.forename: Nitin
authors.initials: N
authors.lastname: Jain
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000175:diagnosis / Q000188:drug therapy*; D055118:Medication Adherence; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors